tbuckley/cabot-search huggingface dataset:
THU0527 Effects of manual therapy, sacroılıac and lumbar exercıses ın patıents wıth sacroılıac joınt dysfunctıon syndrome
Authors: A. Javadov, A. Ketenci
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> The aim of this study was to determine the effects of sacroiliac joint (SIJ) manipulation, sacroiliac and lumbar home exercises on pain, sacroiliac mobilisation levels and functional status in patients with sacroiliac joint dysfunction syndrome (SIJDS). <h3>Methods</h3> In a prospective, randomised interventional trial 69 eligible women were assigned to SIJ manual therapy +sacroiliac home exercise group (Group 1, n=23), SIJ manual therapy +lumbar home exercise group (Group 2, n=23) (n=19), or lumbar home exercise group (Group 3, n=23). All the patients who were included in the study were evaluated on the 0 th, 28 th day and 90 th day of the treatment. Specific tests (motion palpation and pain provocation tests) for SIJ were perfomed. Activity and rest pain was assessed by using the Visual Analogue Scale (VAS). Functional status and quality of life were assessed using the Modified Oswestry Disability Index (MODI) and Short Form-36 (SF-36), respectively. <h3>Results</h3> The VAS scores significantly decreased in all three groups (p&lt;0,05). Gillet test, Vorlauf test, Posterior Shear Test (POSH), Irritation point test and Compression test showed significant decrease after treatment in both training groups (p&lt;0.05). A significant improvement was determined in functional disability score (MODI), quality of life scores, Short Form-36 (SF-36) and neuropathic pain in all three groups (p&lt;0.05). However, a more significant improvement was detected with manual therapy and sacroiliac home exercise program compared to patients in group 2 and group 3. <h3>Conclusions</h3> Our data suggest that manual therapy, sacroiliac and lumbar exercises programs can be effective in patients with sacroiliac joint dysfunction syndrome. In SIJDS, a pathology that should be considered in patients with low back pain, it is necessary to know that special SIE exercises and SIE manipulation therapy can be applied in combination with lumbar exercises and SIE manipulation therapy, or that exercises alone can be given but the benefit expected from exercise alone is less than combined treatment revealed. <h3>Disclosure of Interest</h3> None declared
THU0127 The severity of keratoconjunctivitis sicca in rheumatoid arthritis correlates with the medical outcome study 36-item short form health survey (SF-36) score but not the disability index (HAQ-DI)
Authors: R.O. Akintayo, B.H. Olaosebikan
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Keratoconjunctivitis sicca (KSC) is the most frequent ocular manifestation of rheumatoid arthritis (RA). It is highly heterogenous and exhibits a considerable variability of presentation. Whereas a significant proportion of patients with KCS may be asymptomatic; it is unknown if the degree of dryness of the eyes, irrespective of symptomatology, has an association with the overall quality of life and functional ability. <h3>Objectives</h3> To determine the correlation between the Schirmer's score and the Medical Outcome Study 36-Item Short Form Health Survey (SF-36) score as well as the disability index measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). <h3>Methods</h3> A total of 50 Nigerian patients satisfying the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA were studied. Tear production was measured by unstimulated 5 min Schirmer's test (using 5 mm by 35 mm Whatman filter paper) and ocular staining with flourescein stain. Each patient also completed the SF-36 and HAQ-DI questionnaires. <h3>Results</h3> The mean age of the patients was 47.2±12.5 years. Among them, 42 (84%) were females, giving a female-to-male ratio of 5.25:1. Rheumatoid factor and anti-citrullinated protein antibody were positive in 38 (76%) and 30 (60%) patients respectively. KCS was found in 15 (30%) patients among whom only 6 patients were symptomatic for dry eyes. The mean visual acuity [LogMAR (Snellen equivalent)] among the patients with and without KCS were 0.70 (6/30) and 0.10 (6/7.5). Among all patients, there was a positive correlation between the mean Schirmer's score (between each patients two eyes) and the Physical Component Summary (r=0.292, p=0.008) as well as the Mental Component Summary (r=0.228, p=0.030) of the SF-36. There is however no significant correlation between the mean Schirmer's score and the HAQ-DI (r=0.148, p=0.188). <h3>Conclusions</h3> Ocular manifestation is very common in RA and KCS is particularly rampant. Even in asymptomatic patients, the degree of xerophthalmia may give a reliable insight into both the physical and mental quality of life but not into the degree of functional disability. <h3>References</h3> [1] Vignesh APP, Srinivasan R. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies. Clin Ophthalmol2015;9:393–7. [2] Bron AJ, Tomlinson A, Foulks GN, et al. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf2014;12(2):S1-S31. <h3>Disclosure of Interest</h3> None declared
THU0253 The chronic spinal pain in spondyloarthropathies, osteoarthritis, and fibromyalgia: the role of central sensitisation
Authors: F.F. Ayhan, Ö. F. Çelik, M.A. Güler
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Central sensitisation (CS) is a new phenomenon associated with several medical diagnoses, including post-cancer pain, low back pain, osteoarthritis (OA), whiplash, and fibromyalgia (FMS).<sup>1</sup> Central sensitisation inventory (CSI) suggest the tool generates reliable and valid data that quantify the severity of several symptoms of CS.<sup>2</sup> <h3>Objectives</h3> To the best of our knowledge, there is no study to evaluate CS pain in patients with Spondylarthritis (SpA). The aim of this study was to show the role of CS pain in patients with painful spine of SpA, OA, and FMS. <h3>Methods</h3> Totally 137 patients with chronic spinal pain (42 SpA, 45 OA and 50 FMS) were included. CSI consists of 2 parts<sup>1,2</sup>: CSI-A and CSI-B (restless leg, chronic fatigue, FMS, temporomandibular disorders, migraine/tension type headache, irritable bowel, multiple chemical sensitivity, whiplash, anxiety/panic attack, and depression). <h3>Results</h3> Only 4 patients (9.52%) had active SpA (BASDAI≥4). Twelve patients (28.57%) have used anti-TNF drugs. Age, BASDAI and VAS-pain scores were not related with SS-A or SS-P positivity. Spine in patients with SpA was less painful compared with them of OA and FMS (p=0.001). The CS pain was detected in most with FMS, compared with OA, and SpA patients (p&lt;0.001). Similarly, CSI-A score was the highest in patients with FMS group (p&lt;0.001) and similar in both OA and SpA groups (p=0.197). CS-related syndromes (CSI-B) were also detected similarly in both SpA and OA groups, but less than FMS group (p&lt;0.001). The numbers of CS syndromes were also similar in both SpA and OA (p=0.551) and lower than FMS group (p=0.003). Table 1 shows the clinical parameters in all groups. <h3>Conclusions</h3> Central sensitisation should be considered in patients with chronic persistent pain, not only having FMS, but also half of the patients having SpA and OA. It is not a rare phenomenon and if it is exists, effective pain management strategies could be needed in addition to the specific pharmacologic treatment. <h3>References</h3> [1] O'Leary H, et al. Nervous System Sensitization as a Predictor of Outcome in the Treatment of Peripheral Musculoskeletal Conditions: A Systematic Review. Pain Pract2017;17(2):249–266. [2] Neblett R, et al. The Central Sensitization Inventory (CSI): The Journal of Pain2013;14(5):438–45. [3] Düzce E. SS Ölçeğinin Türkçe Geçerlilik&amp;Güvenilirliği. Trakya FTR AD Uzmanlık Tezi2017. <h3>Disclosure of Interest</h3> None declared
Advances in multidisciplinary therapy for meningiomas
Authors: Priscilla K Brastianos, Evanthia Galanis, Nicholas Butowski, Jason W Chan, Ian F Dunn, Roland Goldbrunner, Christel Herold-Mende, Franziska M Ippen, Christian Mawrin, Michael W McDermott, Andrew Sloan, James Snyder, Ghazaleh Tabatabai, Marcos Tatagiba, Joerg C Tonn, Patrick Y Wen, Kenneth Aldape, Farshad Nassiri, Gelareh Zadeh, Michael D Jenkinson, David R Raleigh, Kenneth Aldape, Karolyn Au, Jill Barnhartz-Sloan, Wenya Linda Bi, Priscilla K Brastianos, Nicholas Butowski, Carlos Carlotti, Michael D Cusimano, Francesco DiMeco, Katharine Drummond, Ian F Dunn, Evanthia Galanis, Caterina Giannini, Roland Goldbrunner, Brent Griffith, Rintaro Hashizume, C Oliver Hanemann, Christel Herold-Mende, Craig Horbinski, Raymond Y Huang, David James, Michael D Jenkinson, Christine Jungk, Timothy J Kaufman, Boris Krischek, Daniel Lachance, Christian Lafougère, Ian Lee, Jeff C Liu, Yasin Mamatjan, Alireza Mansouri, Christian Mawrin, Michael McDermott, David Munoz, Farshad Nassiri, Houtan Noushmehr, Ho-Keung Ng, Arie Perry, Farhad Pirouzmand, Laila M Poisson, Bianca Pollo, David Raleigh, Felix Sahm, Andrea Saladino, Thomas Santarius, Christian Schichor, David Schultz, Nils O Schmidt, Warren Selman, Andrew Sloan, Julian Spears, James Snyder, Suganth Suppiah, Ghazaleh Tabatabai, Marcos Tatagiba, Daniela Tirapelli, Joerg C Tonn, Derek Tsang, Michael A Vogelbaum, Andreas von Deimling, Patrick Y Wen, Tobias Walbert, Manfred Westphal, Adriana M Workewych, Gelareh Zadeh
Journal: Neuro-Oncology (2018)

Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Radiation therapy has largely been used as a complementary and safe therapeutic strategy in meningiomas with evidence primarily stemming from retrospective, single-institution reports. Two of the first cooperative group studies (RTOG 0539 and EORTC 22042) evaluating the outcomes of adjuvant radiation therapy in higher-risk meningiomas have shown promising preliminary results. Historically, systemic therapy has resulted in disappointing results in meningiomas. However, several clinical trials are under way evaluating the efficacy of chemotherapies, such as trabectedin, and novel molecular agents targeting Smoothened, AKT1, and focal adhesion kinase in patients with recurrent meningiomas.
THU0018 Mirnas-146a and -499 gene expression and their polymorphisms as diagnostic markers for rheumatoid arthritis
Authors: G.A. Ayeldeen, Y.H. Nassar, H.A. Ahmed, O.G. Shaker, T.A. Gheita
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To investigate the expression of miRNAs-146a and −499 and their polymorphisms in Egyptian patients with RA and to evaluate their relationship to clinical manifestations and disease activity. <h3>Methods</h3> Fifty-two RA patients and 56 matched controls were studied. Disease activity score-28 was assessed. MicroRNAs expression and polymorphisms were assayed by polymerase chain reaction (PCR). <h3>Results</h3> Patients mean age was 39.5±10.8 years and the disease duration of 7±5.1 years. The DAS28 was 3.1±1.7; 23 were in remission, 5 had mild disease activity, 18 moderate and 6 severe. There was a 15.5±27.2 fold increase in miRNA-146a and 3.3±6.1 in miR-499. The fold change of miRNA-146a was significantly higher in those without joint deformities (n=18) (28.1±42.6) compared to those with(8.8±8.4;p=0.01). Both miRNA-146a and −499 fold change were significantly decreased in those with a positive ANA (n=7)(2.5±2.1 and 0.07±0.08) compared to those with a negative test (18.1±29.6 and 3.8±6.5;p=0.002 and p=0.001 respectively). The fold changes tended to be higher in those in remission compared to active patients. However, miRNA-499 in those with severe disease activity tended to be higher. There was no significant correlation of the fold change of the miRNAs with the clinical manifestations or medications received. Only ANA positivity significantly inversely correlated with the fold increase in mi-RNA-146a(r=−0.42,p=0.003). The fold change in miRNA-146a significantly correlated with miRNA-499(r=0.56,p&lt;0.0001). <h3>Conclusions</h3> Both miRNAs-146a and-499 are highly expressed in RA patients and can be considered as diagnostic markers. Increased expression of miRNA-146a expression is protective in those with negative ANA and both in those without joint deformities. <h3>Disclosure of Interest</h3> None declared
SAT0149 Fibromyalgia and benign joint hypermobility syndrome
Authors: P Borman, D Keskin, H Bodur
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Fibromyalgia syndrome is a chronic rheumatic condition characterised by widespread musculoskeletal pain. <h3>Objectives</h3> The aim of this study was to investigate the relationship between benign joint hypermobility syndrome (BJHS) and FMS. <h3>Methods</h3> Thirty-four fibromyalgia patients and 30 healthy control subjects with a mean age of 32.6 ± 7.8 and 38.8 ± 11.1 years respectively, were recruited to the study. Data about demographical and clinical characteristics of the subjects including age, sex, widespread pain, number of specific tender points and associated symptoms were recorded. The joint hypermobility was evaluated depending on the Beighton score and the diagnosis of BJHS was considered according to the revised criteria for the diagnosis of BJHS (Brighton 1998). <h3>Results</h3> There were 2 male and 32 female subjects in each group. The mean number of tender points (14.7 ± 1.9 vs 2.5 ± 3.1), associated symptoms (7.1 ± 1.7 vs 2.5 ± 1.6) and Beighton score (3.4 ± 1.3 vs 1.7 ± 1.9) were significantly higher in the FMS group. The BJHS was present in 2 (5.8%) of FMS and 1 (2.9%) of the control subjects. <h3>Conclusion</h3> The fibromyalgia patients may be more hypermobile than the control subjects but BJHS is a different clinical entity having no relationship with FMS.
Abstract 13415: Mitral Annular Dynamics in Mitral Annular Calcification: Evaluation With Real-time 3D-Echocardiography
Authors: Rajesh Movva, Yan Topilsky, Gregg S Pressman, Maurice Enriquez-Sarano
Journal: Circulation (2013)

Background: Mitral valve anatomy and physiology are complex. 2D-Echocardiography is of limited value in their evaluation. Using real-time 3D echocardiography, we sought to describe the changes that occur in the calcified annulus (MAC) when compared with normal controls. Methods and Results: 43 MAC subjects were compared with 42 age, sex, and BMI-matched controls. Mitral annular area, anteroposterior [AP] and intercommissural [IC] diameters, height, and height/IC ratio (a measure of the saddle shape of the valve) were measured throughout the cardiac cycle with dedicated quantification software (figure). Compared to normal controls, the calcified annulus was similar in size (average diastolic area = 7.8 ± 1.8 cm2 vs. 7.2 ± 1.5 cm2, p=0.16) but flatter (diastolic height = 2.84 ± 1.22 cm vs. 3.54 ± 0.98 cm, p = 0.007). Annular contraction was reduced in MAC subjects, largely due to decreased contraction along the AP diameter (3 ± 7% vs. 10 ± 9%, p = 0.0006). Height/IC ratio in early systole was less when MAC ...
Ionotropic Receptors Specify the Morphogenesis of Phasic Sensors Controlling Rapid Thermal Preference in Drosophila
Authors: Gonzalo Budelli, Lina Ni, Cristina Berciu, Lena van Giesen, Zachary A. Knecht, Elaine C. Chang, Benjamin Kaminski, Ana F. Silbering, Aravi Samuel, Mason Klein, Richard Benton, Daniela Nicastro, Paul A. Garrity
Journal: Neuron (2019)
SAT0442 Risk factors for heart valve diseases in patients with antiphospholipid syndrome
Authors: K. Hiramoto, J. Kikuchi, Y. Kaneko, T. Takeuchi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Antiphospholipid syndrome (APS) patients are known to be at a high risk of heart valve diseases (HVDs), however, risk factors of HVDs in APS patients is unclear. <h3>Objectives</h3> The purpose of this study is to elucidate risk factors for HVDs in patients with APS. <h3>Methods</h3> We reviewed consecutive APS patients diagnosed according to the Sydney criteria in 2006 who had been followed in Keio University Hospital in October 2017. The presence of HVDs was identified by the latest transthoracic and/or transesophageal echocardiography. HVDs were defined any kind of valve diseases such as mitral valve regurgitation (MR) and stenosis more than mild degree, aortic valve regurgitation (AR) and stenosis more than mild degree and Libman-Sacks endocarditis. Antiphospholipid antibodies (aPLs) included lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anticardiolipin β2-glycoprotein I complex antibodies (aCL-β2GPI). We divided the patients into two groups by the presence of HVDs, and evaluated the risk factors of them. <h3>Results</h3> Fifty-five APS patients were identified. Among them, 43 patients underwent echocardiography and enrolled in the analysis. Six patients were primary APS, 36 were secondary APS with systemic lupus erythematosus, and one with Sjögren syndrome. HVDs were detected in 26 (60.5%) patients including 20 patients with MR, 8 patients with AR and a patient with Libman-Sacks endocarditis. The use of prednisolone, miscarriage episodes and the presence of arterial or venous thrombosis in patients with HVDs did not differ from those without HVDs. Immunologically, there was no significant difference in anti-double-stranded DNA antibody, anti-Smith antibody, anti-ribonucleoprotein antibody, anti-SSA/La antibody and anti-SSB/Lo antibody between patients with or without HVDs. While the positivity of aCL or aCL-β2GPI was not different between patients with HVDs and those without, positive LA was much higher in patients with HVDs and in patients with MR than those without (88.5% vs 35.3%, p&lt;0.01; 85.0% vs 52.2%, p=0.027, respectively). In addition, patients with HVDs had double and triple positive tests of aPLs significantly more frequently than those without HVDs (p=0.010 and p=0.023, respectively[Y1]) . Hospitalisation risk in patients with HVDs because of heart failure or syncope were 0.011/patient year. <h3>Conclusions</h3> Positive LA test and positivity for 2 or more tests of aPLs are risk factors for HVDs in patients with APS. Regular monitoring cardiac ultrasonography is needed in those patients. <h3>Disclosure of Interest</h3> None declared
SAT0419 Renal and overall survival analysis in a cohort of patients with lupus nephritis with up to 40 years of follow up
Authors: F. Farinha, R. Pepper, B.S. Bernstein, D.A. Isenberg, A. Rahman
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Although the prognosis has improved in the last decades, Lupus patients still have a 3-fold increase in mortality, compared with the general population.<sup>1</sup>Lupus nephritis (LN) is one of the most severe manifestations of this complex systemic disease, occurring in up to 60% of patients. <h3>Objectives</h3> 1) To obtain the overall and renal survival curves for a LN cohort; 2) To investigate factors affecting survival; 3) To identify the causes of death in this cohort. <h3>Methods</h3> Single-centre retrospective observational study, including all patients with biopsy-proven LN, followed at UCLH Rheumatology department from 1975 to 2017. Individual clinical files were reviewed to obtain demographic, clinical, laboratory and pathological data. We also recorded data on treatment with corticosteroids, immunosuppressants and antimalarials. We analysed overall survival and renal survival through the Kaplan-Meier method. COX regression analyses were conducted to investigate possible predictors of shorter survival. Significance level was defined at 0.05. <h3>Results</h3> 209 patients were included (table 1). Cumulative survival at 5, 10, 15 and 20 years after the diagnosis of LN was 92%, 86%, 81% and 76%, respectively. Main causes of death were infection (29%), malignancy (21%) and cardiovascular (21%). Regarding progression to end-stage renal disease (ESRD), cumulative renal survival at 5, 10, 15 and 20 years was 94%, 86%, 79% and 72%, respectively. Table 2 shows the predictors of shorter survival identified for this cohort. Image 1 represents the Kaplan-Meier curves according to the factors affecting renal survival. <h3>Conclusions</h3> Cumulative survival rates and causes of death for this cohort are comparable with other cohorts of LN. ESRD confers the higher risk for death; African or Caribbean ethnicities and not taking antimalarials predict shorter overall and renal survival among these patients. <h3>Reference</h3> [1] Yurkovich M, Vostretsova K, Chen W, Avina-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken)2014;66(4):608–16. <h3>Disclosure of Interest</h3> None declared
Guideline: Experts recommend against prostate cancer screening with prostate-specific antigen test
Authors: Robert H. Fletcher
Journal: Annals of Internal Medicine (2019)

ACP Journal Club15 January 2019Guideline: Experts recommend against prostate cancer screening with prostate-specific antigen testRobert H. Fletcher, MD, MScRobert H. Fletcher, MD, MScHarvard Medical School, Chapel Hill, North Carolina, USA (R.H.F.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2019-170-2-002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationTikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;362:k3581. https://pubmed.ncbi.nlm.nih.gov/30185545Clinical Impact RatingsGIM/FP/GP: Public Health: References1 Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. [PMID: 30185521] Google Scholar2 Martin RM, Donovan JL, Turner EL, et al; CAP Trial Group. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319:883-95. [PMID: 29509864] Google Scholar3 Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med.2012;27:1361-7. [PMID: 22618581] Google Scholar Author, Article, and Disclosure InformationAffiliations: Harvard Medical School, Chapel Hill, North Carolina, USA (R.H.F.)This article was published at Annals.org on 1 January 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySpatial Decomposition For Robust Domain Adaptation In Prostate Cancer DetectionAssociation of Total Dietary Intake of Sugars with Prostate-Specific Antigen (PSA) Concentrations: Evidence from the National Health and Nutrition Examination Survey (NHANES), 2003-2010Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent UpdatesDevelopment and Validation of a Highly Informative Immuno-Enzymatic Analysis for the Determination of Free Prostat-Specific AntigenUpregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer 15 January 2019Volume 170, Issue 2Page: JC2KeywordsAbsolute risk reductionAntigensCancer screeningDecision makingGrading of Recommendations Assessment Development and EvaluationMortalityNumber needed to screenProstate cancerQuality of lifeSystematic reviews ePublished: 15 January 2019 Issue Published: 15 January 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...